Economic evaluations of massive HPV vaccination: Within-study and between study variations in incremental cost per QALY gained

Preventive Medicine

Volumn 48, Issue 5, 2009, Pages 444-448

  Puig Junoy, Jaume ^a   Lopez Valcarcel, Beatriz G ^b  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

Author keywords

Cost effectiveness; Cost utility; HPV vaccination; Screening

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER PREVENTION; CANCER SCREENING; CHILD; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; FEMALE; HEALTH CARE POLICY; HUMAN; INFECTION PREVENTION; INFORMATION RETRIEVAL; MEDICAL INFORMATION; MEDICAL LITERATURE; PEER REVIEW; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; TREATMENT DURATION; UNCERTAINTY; UTERINE CERVIX CANCER; WART VIRUS;

CHILD; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MASS IMMUNIZATION; MASS SCREENING; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; REVIEW LITERATURE AS TOPIC; UTERINE CERVICAL NEOPLASMS;

EID: 65549123782     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ypmed.2009.02.011     Document Type: Article

References (37)

1. Barnabas R.V., and Kulasingam S.L. Economic evaluations of human papillomavirus vaccines. Expert Rev. Pharmacoecon. Outcomes Res. 7 (2007) 251-267
2. Bergeron C., Largeron N., Mcallister R., Mathevet P., and Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Intl. J. Technol. Assess. Health Care 24 1 (2008) 19
3. Boeke A.J. Advisory report from the Health Council of the Netherlands to include human papillomavirus vaccination in the national immunisation programme for the prevention of cervical cancer. Ned. Tijdschr. Geneeskd. 152 (2008) 981-983
4. Boot, H.J., Wallenburg, I., de Merlker, H.E., Mangen, M-J., Gerritsen, A.A.M., van der Maas, N.A., Berkhof, J., Meijer, C.J.L.M., Kimman, T.G., 2007. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine 27, 6245-6256.
5. Brisson M., Van De Velde N., De Wals P., and Boily M. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25 (2007) 5399-5408
6. Chesson H.W., Ekwueme D.U., Saraiya M., and Markowitz L.E. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg. Infect. Dis. 14 (2008) 244-251
7. Clifford G.M., Gallus S., Herrero R., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366 (2005) 991-998
8. Dasbach E.J., Insinga R.P., and Elbasha E.H. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 115 (2008) 947-956
9. Department of Health (2008) HPV vaccine recommended for NHS immunisation programme. http://nds.coi.gov.uk/environment/fullDetail.asp?ReleaseID=325799&NewsAreaID=2&NavigatedFromDepartment=True
10. Diaz M., Kim J.J., Albero G., et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br. J. Cancer 99 (2008) 230-238
11. Drummond M., Chevat C., and Lothgren M. Do we fully understand the economic value of vaccines?. Vaccine 25 (2007) 5945-5957
12. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis. 13 (2007) 28-41
13. Ferko N., Postma M., Gallivan S., Kruzikas D., and Drummond M. Evolution of the health economics of cervical cancer vaccination. Vaccine 26S (2008) F3-15
14. Ginsberg G.M., Fisher M., Ben-Shahar I., and Bornstein J. Cost-utility analysis of vaccination against HPV in Israel. Vaccine 25 (2007) 6677-6691
15. Goldhaber-Fiebert J.D., Stout N.K., Salomon J.A., Kuntz K.M., and Goldie S.J. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J. Natl. Cancer Inst. 100 (2008) 308-320
16. Goldie S.J., Kohli M., Grima D., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J. Natl. Cancer Inst. 96 (2004) 604-615
17. Goldie S.J., Kim J.J., and Myers E. Cost-effectiveness of cervical cancer screening. Vaccine 24S3:S3 (2006) 164-170
18. Goldie S.J., O'shea M., Campos N.G., Diaz M., Sweet S., and Kim S.Y. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 26 (2008) 4080-4093
19. Haug C.J. Human papillomavirus vaccination-reasons for caution. N. Engl. J. Med. 359 (2008) 861-862
20. Insinga R.P., Dasbach E.J., Elbasha E.H., Puig A., and Reynales-Shigematsu L.M. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 26 (2007) 128-139
21. Jit M., Choi Y.H., and Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337 (2008) a769
22. Kim J.J., and Goldie S.J. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med. 359 (2008) 821-832
23. King L.A., Levy-Bruhl D., O'flanagan D., et al. Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: results of the VENICE 2007 survey. Euro Surveill. 13 (2008)
24. Kiviat N.B., Hawes S.E., and Feng Q. Screening for cervical cancer in the era of the HPV vaccine-the urgent need for both new screening guidelines and new biomarkers. J. Natl. Cancer Inst. 100 (2008) 290-291
25. Koulova A., Tsui J., Irwin K., Van Damme P., Biellik R., and Aguado M.T. A brief report: country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 26 (2008) 6529-6541
26. Kulasingam S., Connelly L., Conway E., Hocking J.S., Myers E., Regan D.G., et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening program. Sexual Health 4 (2007) 165-175
27. Kulasingam S.L., Benard S., Barnabas R.V., Largeron N., and Myers E.R. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost effectiveness analysis. Cost Eff. Resour. Alloc. 6 4 (2008) 10.1186/1478-7547-6-4
28. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., and Unger E.R. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mort. Wkly. Rep., Recomm. Rep. 56 (2007) 1-24
29. NAC. An Advisory Committee Statement (ACS). Statement on human papillomavirus vaccine. Can. Commun. Dis. Rep. 33 (2007) 32
30. Newall A.T., Beutels P., Wood J.G., Edmunds W.J., and Macintyre C.R. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet, Infect. Dis. 7 (2007) 289-296
31. Roughead E.E., Gilbert A.L., and Vitry A.I. The Australian funding debate on quadrivalent HPV vaccine: a case study for the national pharmaceutical policy. Health Policy 88 (2008) 250-257
32. Sanders G.D., and Taira A.V. Cost effectiveness of a potential vaccine for Human papillomavirus. Emerg. Infect. Dis. 9 1 (2003) 37-48 Jan
33. Suárez E., Smith J.S., Bosch F.X., Nieminen P., Chen C., Torvinen S., et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccionation scenarios. Vaccine 26S (2008) F29-45
34. Stout N.K., Goldhaber-Fiebert J.D., Ortendahl J.D., and Goldie S.J. Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch. Intern. Med. 168 (2008) 1881-1889
35. Szucs T.D., Largeron N., Dedes K.J., Rafia R., and Bénard S. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to cervical cancer screening programme in Switzerland. Curr. Med. Res. Opin. 24 5 (2008) 1473-1483
36. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating Human papillomavirus vaccination programs. Emerg. Infect. Dis. 10 11 (2004) 1915-1923 Nov
37. Techakehakij W., and Feldman R.D. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine 26 (2008) 6258-6265